Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer.

Ayşe LatifAmy L ChadwickSarah J KitsonHannah J GregsonVanitha N SivalingamJames BoltonRhona J McVeyStephen A RobertsKay M MarshallKaye J WilliamsIan J StratfordEmma J Crosbie

Published in: BMC clinical pathology (2017)

Our data suggest that MCT1 expression is an important marker of poor prognosis in EC. MCT1 inhibition may have potential as a treatment for advanced or recurrent EC.

Keyphrases

poor prognosis
endometrial cancer
long non coding rna
electronic health record
big data
climate change
deep learning
artificial intelligence